|
|
The Joint DMDG/GMP Open Meeting
2016
19 - 21 October,
Espace St Martin, 199bis rue Saint Martin, 75003, Paris, France
|
|
|
| Programme |
|
Offers of posters are welcome -
the email addresses of the Poster Session organisers can be found in
the
Session Synopsis.
Posters will be available for viewing throughout the conference.
|
|
Wednesday 19th October |
| |
|
|
|
11-12:00 |
|
Arrival, Registration &
Lunch |
|
|
|
|
|
13:00 |
|
Chairs’ Opening Address
Suzanne Iverson Hemberg, Sahlgrenska
University Hospital, Sweden
Vassilios Aslanis, Novartis, Switzerland |
|
13:30 |
|
Keynote Speaker
Spatially resolved assessment of drug-induced changes in
metabolism by mass spectrometric imaging
Prof Zoltan Takats, Ph.D, Imperial College
London, UK |
|
14:30 |
|
Tea and coffee |
|
15:00 |
|
Session 1 – The impact
of pre-clinical PKPD modelling on drug discovery and development
Chairs: James Yates and Marc Trellu
Application of model based drug discovery from target
idea to early clinical studies – a case study
Rasmus
Jansson Löfmark,: AstraZeneca R&D Mölndal, Sweden
Drug profiling in discovery using model based
approach to project from in vitro to patients
Caterina
Bissantz , Roche, Switzerland
How early ePKPD may help the drug discovery process?
Specific examples and case studies will be highlighted to help
demonstrate key points for opportunities and benefits
Pierre-Yves
Abecassis, Sanofi R&D, France |
|
17:00 |
|
Poster Blitz -
5-minute presentations from selected posters to engage audience
prior to the poster session |
|
17:30 |
|
Poster Session
Wine and food available
Organisers: Peter Kilford, Florence
Gattacceca and
Sunil Mathur |
|
19:00 |
|
End of session |
|
|
|
|
|
Thursday 20th October |
|
|
|
|
|
09:00 |
|
Session 2 – Implementing
biodistribution to better understand PK
Chairs: Sherri Dudal; Graeme Clark and
Florence Gattacceca
Hunt for off-target binding - biodistribution and in vitro attempts
to solve atypical PK
Kevin Brady, F. Hoffman-La Roche,
Switzerland
Mass spectrometry imaging applied to investigating drug
efficacy and toxicity across pharmaceutical R&D
Richard Goodwin, AstraZeneca, UK
Optimising PK of therapeutics using Veltis®-albumin-based
technologies – from rational design to PK/PD and biodistribution
Jenny McLaughlan, Albumedix (formerly
Novozymes), UK
Ocular Drug Distribution: Impact of Melanin Binding
Arto Urtti, University of Helsinki, Finland |
|
10:30 |
|
Coffee |
|
10:50 |
|
Session 3 – Skin
Metabolism
Chairs: Vibeke Hougaard Sunesen and André
Huss Eriksson
Drug metabolism in the skin: Relevance for development of
dermally applied drug products
Clemens Günther, Bayer, Germany
Skin Metabolism: Comparison of In Vitro Methods and
Models
Carine Jacques-Jamin, Pierre-Fabre, France
In Vitro Measurements to Determine Cutaneous
Bioavailability
Joan Eilstein, L'Oréal, France
Contribution of dermal metabolism to local toxicities
Simon Wilkinson, University of Newcastle, UK |
|
12:20 |
|
Lunch |
|
13:50 |
|
Session 4 – New
Approaches for the Prediction of ADME Parameters
Chairs: Angus Nedderman and Marion Millet
Direct and quantitative evaluation of the human CYP450
contribution (fm) to drug clearance using the in vitro SILENSOMESâ„¢
model
Yannick
Parmentier, Servier, France
Upcyte® Human Hepatocytes – Application for clearance
prediction of metabolically stable compounds
Michelle Schaefer, Boehringer Pharma, Germany
Computational prediction of sites of metabolism
Prof Robert Glen, Imperial College London, UK |
|
15:20 |
|
Tea and coffee |
|
15:40 |
|
Session 5 – Bioanalysis
of Biomarkers: Challenges, pitfalls and new perspectives
Chairs: Karelle Menochet & Tim Sangster
Biomarker strategy and bioanalytical challenges for
biologics in preclinical drug discovery and development for use in
PKPD
Sherri Dudal, UCB, UK
Biomarker assay validation in practice: EBF Recommendation in
practice and feedback from the recent EBF Focus Workshop (June,
Lisbon)
Marianne Scheel Fjording, NovoNordisk, Denmark and Philip Timmerman,
Janssen R&D, Belgium
Bioanalysis of miRNAs: The Same
but Different
Keith Sutton, Charles River Laboratories, UK |
|
17:10 |
|
Keynote Speaker
The TeGenero and Bial trials - the importance of pharmacology
for taking medicines safely into humans
Michael Eddleston,
University of Edinburgh, UK |
|
18:00 |
|
End of session |
|
|
|
|
|
19:30 |
|
Conference Dinner &
Entertainment |
|
|
|
|
|
Friday 21st
October |
|
|
|
|
|
09:00 |
|
Session 6 - The impact
of Transporters in drug discovery: its not just about small
molecules
Chair: Mohammed Ullah
Transporter strategy in drug discovery and development:
Understanding the impact of active transport on human
pharmacokinetics
Karelle Menochet, UCB, UK
Cross-membrane transport of NBEs: a cell-based approach
to study impact of FcRn recycling in vitro and its correlation with
in vivo clearance
Silke Simon, Roche, Switzerland
Assessment of Antisense Oligonucleotide Disposition in
cells
Erich Koller, Roche, Switzerland |
|
10:30 |
|
Tea and coffee |
|
10:50 |
|
Session 7 – PBPK
application in clinical development to support regulatory submission
Chairs: Antoine Deslandes and Sylvaine Cartot-Cotton
A Case of Regulatory Acceptance of a PBPK Modelling Approach to
Answer Key Drug-Drug Interaction Questions
Venkatesh Pilla Reddy, AstraZeneca, UK
Physiologically-based pharmacokinetic modeling for
prediction of drug-drug interactions: Eliglustat (Cerdelga®) as a
case study
Vanaja Kanamaluru, Sanofi R&D, USA
PBPK, a tool for designing better clinical trials –
application to pediatric studies
Marylore Chenel, Servier,
France |
|
|
|
|
|
12:30 |
|
Closing Remarks |
|
13:00 |
|
Lunch and Delegates
Depart |
|
|
|
|
|
|
|
Gold Sponsors
Silver Sponsors
Bronze Sponsors
| |
